Page last updated: 2024-10-22

theophylline and Chronic Kidney Diseases

theophylline has been researched along with Chronic Kidney Diseases in 1 studies

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's1 (100.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Nigwekar, SU1
Weiser, JM1
Kalim, S1
Xu, D1
Wibecan, JL1
Dougherty, SM1
Mercier-Lafond, L1
Corapi, KM1
Eneanya, ND1
Holbrook, EH1
Brown, D1
Thadhani, RI1
Păunescu, TG1

Clinical Trials (1)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
Smell in Covid-19 and Efficacy of Nasal Theophylline[NCT04789499]Phase 251 participants (Actual)Interventional2021-03-15Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

36-Item Short Form Health Survey (SF-36)

The SF-36 is a well-established 36-item questionnaire evaluating physical functioning, bodily pain, role limitations due to physical health problems, role limitations due to personal or emotional problems, emotional well-being, social functioning, energy/fatigue, and general health perceptions. This test allows us to study the overall quality of life for those suffering from COVID-19 related OD. There is no single overall score for SF-36. The SF 36 generates 8 subscales with scores ranging from 0 (worst) to 100 (best). General health domain scores are reported here. (NCT04789499)
Timeframe: Baseline assessment

Interventionscore on a scale (Median)
Theophylline75
Placebo80

Change in Questionnaire for Olfactory Dysfunction (QOD) From Baseline to 6 Weeks Post Intervention

Questionnaire for Olfactory Dysfunction (QOD) assesses health-related quality of life of participants based on four factors such as eating, mental health, social interactions, or fear of dysfunction.. The survey also includes questions on parosmia, a phenomena of COVID-related OD. The QOD consists of 17 statements that participants score from 0-3, resulting in a total score from 0 to 51. Higher scores reflect better olfactory-specific QOL. (NCT04789499)
Timeframe: Comparison at 6 weeks post-intervention from baseline

Interventionscore on a scale (Median)
Theophylline0.86
Placebo1.43

Olfactory Dysfunction Outcomes Rating (ODOR)

The ODOR is a 28-item QOL instrument with a total score ranging from 0 to 112 points. Higher scores indicate worse QOL with higher degree of dysfunction and limitation. A decrease of 15 or more points is deemed to be a clinically significant improvement in QOL. (NCT04789499)
Timeframe: Comparison of response rate at 6 weeks post-intervention from baseline between the 2 study groups

Interventionscore on a scale (Median)
Theophylline-6.5
Placebo-4.5

University of Pennsylvania Smell Identification Test (UPSIT)

"UPSIT 0-40 with higher scores indicating better smell.~This test is an objective, clinically validated 40-question forced-choice odor identification test where microencapsulated odorants on a strip are released by scratching. Out of a total of 40 points, normosmia is defined as ≥34 for males and ≥35 for females, and an increase in ≥4 points will be deemed a clinically significant improvement in symptoms." (NCT04789499)
Timeframe: Comparison at 6 weeks post-intervention from baseline

Interventionscore on a scale (Median)
Theophylline3
Placebo0

UPSIT

"UPSIT 0-40 with higher scores indicating better results.~The response rate defined as the number of participants in each group self-reporting of at least slightly better improvement in the Clinical Global Improvement Scale at 6 weeks post intervention as compared to baseline, devided by the total number of participants in that specific group. The CGI-Improvement Scale has seven response options (from 1 as Very Much Improved to 7 as Very Much Worsened) for answers to the question Compared to your sense of smell before you started the nasal irrigations, how would you rate your sense of smell now . Participants reporting 3 as Minimally Improved, 2 as Much Improved, or 1 as Very Much Improved in the CGI-I will be deemed responders to treatment, and the rate of responders will be compared between the two arms." (NCT04789499)
Timeframe: Comparison of response rate at 6 weeks post-intervention from baseline between the 2 study groups

Interventionpercentage of participants (Number)
Theophylline59
Placebo43

Other Studies

1 other study available for theophylline and Chronic Kidney Diseases

ArticleYear
Characterization and Correction of Olfactory Deficits in Kidney Disease.
    Journal of the American Society of Nephrology : JASN, 2017, Volume: 28, Issue:11

    Topics: Female; Humans; Kidney Failure, Chronic; Male; Middle Aged; Olfaction Disorders; Phosphodiesterase I

2017